The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin's lymphoma: Correlation with tumor-associated macrophages

Oncologist

Volumn 17, Issue 6, 2012, Pages 871-880

  Koh, Youngwha ^a   Kang, Hyo Jeong ^a   Park, Chansik ^a   Yoon, Dok Hyun ^a   Kim, Shin ^a   Suh, Cheolwon ^a   Go, Heounjeong ^b   Kim, Ji Eun ^b   Kim, Chul Woo ^b   Huh, Jooryung ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Hodgkin's lymphoma; Lymphocyte monocyte ratio; Lymphocytes; Monocytes; Prognosis

Indexed keywords

ALBUMIN; CD163 ANTIGEN; CD68 ANTIGEN; HEMOGLOBIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CHILD; CORRELATION ANALYSIS; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTE COUNT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SCHOOL CHILD; TUMOR ASSOCIATED LEUKOCYTE;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CHILD; CHILD, PRESCHOOL; FEMALE; HODGKIN DISEASE; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTORS, CELL SURFACE; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; YOUNG ADULT;

EID: 84862898470     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0034     Document Type: Article

References (39)

1. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506-1514.
2. Gallamini A, Hutchings M, Rigacci L et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746-3752.
3. Schreck S, Friebel D, Buettner M et al. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematol Oncol 2009; 27:31-39.
4. Alvaro-Naranjo T, Lejeune M, Salvadó-Usach MT et al. Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: A quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk Lymphoma 2005;46:1581-1591.
5. Steidl C, Lee T, Shah SP et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 2010;362:875-885.
6. Kamper P, Bendix K, Hamilton-Dutoit S et al. Tumorinfiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 2011;96:269-276.
7. Yoon DH, Koh YW, Kang HJ et al. CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma. Eur J Haematol 2012;88:292-305.
8. Zaki MA, Wada N, Ikeda J et al. Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma. Virchows Arch 2011;459:361-366.
9. Tzankov A, Matter MS, Dirnhofer S. Refined prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma. Pathobiology 2010;77:301-308.
10. Jakovic LR, Mihaljevic BS, Perunicic Jovanovic MD et al. The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma. Leuk Lymphoma 2011;52:1913-1919.
11. Dave SS, Wright G, Tan B et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159-2169.
12. Lamagna C, Aurrand-Lions M, Imhof BA. Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol 2006;80:705-713.
13. Shivakumar L, Ansell S. Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferationinducing ligand in hematologic malignancies. Clin Lymphoma Myeloma 2006;7:106-108.
14. Wilcox RA, Wada DA, Ziesmer SC et al. Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood 2009; 114:2936-2944.
15. Porrata LF, Ristow K, Colgan JP et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica 2012;97:262-269.
16. Huh J, Cho K, Heo DS et al. Detection of Epstein-Barr virus in Korean peripheral T-cell lymphoma. Am J Hematol 1999;60:205-214.
17. Tzankov A, Zlobec I, Went P et al. Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores. Leuk Lymphoma 2010;51: 199-212.
18. Devilard E, Bertucci F, Trempat P et al. Gene expression profiling defines molecular subtypes of classical Hodgkin's disease. Oncogene 2002;21:3095-3102.
19. Sánchez-Aguilera A, Montalbán C, de la Cueva P et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006;108:662-668.
20. Chetaille B, Bertucci F, Finetti P et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 2009; 113:2765-3775.
21. Schmidt H, Bastholt L, Geertsen P et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: A prognostic model. Br J Cancer 2005;93: 273-278.
22. Jensen TO, Schmidt H, Miller HJ et al. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol 2009;27:3330-3337.
23. Dai F, Liu L, Che G et al. The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer 2010;10:220.
24. Tsutsumi C, Sonoda KH, Egashira K et al. The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization. J Leukoc Biol 2003;74:25-32.
25. Oh H, Takagi H, Takagi C et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1999;40:1891-1898.
26. Ahn GO, Brown JM. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: Role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008;13:193-205.
27. Yang L, DeBusk LM, Fukuda K et al. Expansion of myeloid immune suppressor Gr_CD11b_ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004;6:409-421.
28. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5:953-964.
29. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8:958-969.
30. Lau SK, Chu PG, Weiss LM. CD163: A specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol 2004;122:794-801.
31. Asano N, Oshiro A, Matsuo K et al. Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: A clinicopathologic study. J Clin Oncol 2006;24:4626-4633.
32. Haybittle JL, Hayhoe FG, Easterling MJ et al. Review of British National Lymphoma Investigation studies of Hodgkin's disease and development of prognostic index. Lancet 1985;1:967-972.
33. MacLennan KA, Bennett MH, Tu A et al. Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. A study of 1659 patients. Cancer 1989;64:1686-1693.
34. Wijlhuizen TJ, Vrints LW, Jairam R et al. Grades of nodular sclerosis (NSI-NSII) in Hodgkin's disease. Are they of independent prognostic value? Cancer 1989; 63:1150-1153.
35. Ferry JA, Linggood RM, Convery KM et al. Hodgkin disease, nodular sclerosis type. Implications of histologic subclassification. Cancer 1993;71:457-463.
36. d'Amore ES, Lee CK, Aeppli DM et al. Lack of prognostic value of histopathologic parameters in Hodgkin's disease, nodular sclerosis type. A study of 123 patients with limited stage disease who had undergone laparotomy and were treated with radiation therapy. Arch Pathol Lab Med 1992;116:856-861.
37. Masih AS, Weisenburger DD, Vose JM et al. Histologic grade does not predict prognosis in optimally treated, advanced-stage nodular sclerosing Hodgkin's disease. Cancer 1992;69:228-232.
38. Hess JL, Bodis S, Pinkus G et al. Histopathologic grading of nodular sclerosis Hodgkin's disease. Lack of prognostic significance in 254 surgically staged patients. Cancer 1994;74:708-714.
39. van Spronsen DJ, Vrints LW, Hofstra G et al. Disappearance of prognostic significance of histopathological grading of nodular sclerosing Hodgkin's disease for unselected patients, 1972-92. Br J Haematol 1997; 96:322-327.